Model-informed Individualized Treatment of Anti-infective Drugs
ConditionOsteoarticular Infections
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorShandong University
About this trial
The study aims to optimize individualized treatment of anti-infective drugs in osteoarticular infections by analyzing drug exposure in patients blood and/or tissues using population pharmacokinetics.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients with suspected/confirmed osteoarticular infections who are undergoing anti-infective drug therapy.
Disqualifiers
Pregnant/lactating women.
There are other factors that the researchers think are not suitable for inclusion.
Trial population
Patients with suspected/confirmed osteoarticular infections who are undergoing anti-infective drug therapy.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Anti-Infective Drugs
DrugAnti-infective drugs are administered using the traditional clinical dosing regimen, with no interventions.
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
Clearance (L/h)
Time frame
Through study completion, an average of 30 days2
Volume of Distribution (L)
Time frame
Through study completion, an average of 30 daysSecondary outcomes
1
ratio of the area under the concentration-time curve from 0 to 24 hours
For time-dependent antimicrobials, the PD target is defined as the time of free drug concentration beyond MIC during the dose interval. For concentration-dependent antimicrobials, the PD target is defined as the ratio of the area under the concentration-time curve from 0 to 24 hours to the MIC.
Time frame
Through study completion, an average of 30 days2
erythrocyte sedimentation rate
Clinical treatment outcome
Time frame
Through study completion, an average of 30 days3
Adverse events
Time frame
Through study completion, an average of 30 daysSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov